

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-20 (cancelled).

21 (New). A method of preventing transport of a Herpes Simplex virus within a neuron or cell, the method comprising providing to said neuron or cell a compound specifically preventing binding between the structural tegument protein, US11 of the virus and the motor protein, kinesin in the neuron or cell such that virus transport in the neuron or cell is prevented.

22 (New). An antiviral composition comprising a compound which specifically prevents binding between the structural tegument protein, US11 of a Herpes Simplex virus and the motor protein, kinesin in a neuron or cell, and an additive, diluent or excipient.

23 (New). The method according to claim 21 wherein the compound is a mimic of kinesin or a part of Kinesin to which US11 binds.

24 (New). The method according to claim 21 wherein the compound is a mimic of US11 or a part of US11 to which kinesin binds.

25 (New). The antiviral composition according to claim 12 wherein the compound is a mimic of kinesin or a part of kinesin to which US11 binds.

26 (New). The antiviral composition according to claim 22 wherein the compound is a mimic of US11 or a part of US11 to which kinesin binds.

27 (New). A method of screening for a compound that inhibits transport of a Herpes Simplex virus within a neuron or cell, the method comprising determining whether a compound to be screened prevents binding between the structural tegument protein, US11 of the virus and the motor protein, kinesin in the neuron or cell.

28 (New). The method according to claim 27 wherein the compound is a mimic of kinesin or a part of kinesin to which US11 binds.

29 (New). The method according to claim 27 wherein the compound is a mimic of US11 or a part of US11 to which kinesin binds.